<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The relationship between KRAS and NF-κB in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> is not clear </plain></SENT>
<SENT sid="1" pm="."><plain>Western blotting was used to determine whether KRAS knockdown in SW620 cells altered the levels of NF-κB-p65 and other molecules </plain></SENT>
<SENT sid="2" pm="."><plain>Furthermore, we investigated the association between the KRAS status and NF-κB expression in 167 colorectal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissues and their correlation with overall survival (OS) of patients with KRAS mutations and activated NF-κB </plain></SENT>
<SENT sid="3" pm="."><plain><z:mp ids='MP_0011356'>RAS</z:mp>, p-ERK, p-IκB�� and p65 expression was decreased in SW620 cells with KRAS knockdown </plain></SENT>
<SENT sid="4" pm="."><plain>The MEK inhibitor U0126 downregulated p-ERK, p-IκBα and p65 levels in SW620 cells </plain></SENT>
<SENT sid="5" pm="."><plain>p65 activation in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with KRAS mutations was higher (50.8%) than in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with the <z:mp ids='MP_0002169'>wild-type</z:mp> KRAS gene (30.6%) (P=0.012) </plain></SENT>
<SENT sid="6" pm="."><plain>Compared to patients with other types of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, OS was lower (median 28.4 months) in patients with KRAS mutations and NF-κB activation, vs. a median of 46.3 months in patients with other types of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> (P=0.005) </plain></SENT>
<SENT sid="7" pm="."><plain>NF-κB activation was reduced in SW620 cells with KRAS knockdown, possibly via the <z:mp ids='MP_0011356'>RAS</z:mp>-ERK-IκBα pathway </plain></SENT>
<SENT sid="8" pm="."><plain>The presence of both KRAS mutations and the active form of NF-κB in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> indicates poor patient prognosis </plain></SENT>
</text></document>